ArticleCurrent therapeutic research, clinical and experimental2022
Selectivity and Maximum Response of Vibegron and Mirabegron for β
Article in Current therapeutic research, clinical and experimental, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- Navigating the challenges of overactive bladder management in women.World journal of urology · 2026Review
- Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- 'BJUI Clinical Dilemma': the overactive bladder.BJU international · 2026Article
- Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.World journal of urology · 2025Review
- Atrial fibrillation signals associated with overactive bladder drugs across JADER and FAERS: disproportionality and time-to-onset analyses.Frontiers in pharmacology · 2025Article
- Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey.Lower urinary tract symptoms · 2024Article
- Physiological and metabolic functions of the βJournal of physiology and biochemistry · 2024Review
- Article
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- Therapeutic Potential for Beta-3 Adrenoreceptor Agonists in Peripheral Arterial Disease and Diabetic Foot Ulcers.Biomedicines · 2023Review
- Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug.Journal of clinical medicine · 2023Review
- A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder.International neurourology journal · 2023Article
- Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.Drugs & aging · 2023Review
- Treating and Managing Urinary Incontinence: Evolving and Potential Multicomponent Medical and Lifestyle Interventions.Research and reports in urology · 2023Review
- Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density.PloS one · 2023Article
- β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition.Cardiovascular diagnosis and therapy · 2022Article
- Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis.Drugs in context · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The β Objective: This study assessed the selectivity of vibegron and mirabegron for β-adrenergic receptors and the maximal effect and potency for β Methods: Functional cellular assays were performed using Chinese hamster ovary-K1 cells expressing β Results: Activation of β Conclusions: Vibegron showed no measurable β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.